



Figure 7.

Prolonged survival in MM bearing NSG mice received human effector cells and CS1-NKG2D biAb. **A**, Kaplan-Meier curve for NSG mice that received MM.1S MM cells alone ($n = 4$), MM.1S MM cells + human PBMCs + PBS ($n = 5$), MM.1S MM cells + PBMCs + control biAb ($n = 5$), or MM.1S MM cells + PBMCs + CS1-NKG2D biAb ($n = 5$). A total of 5×10^6 MM.1S MM cells and 5×10^6 PBMCs were used. Dose of control biAb or CS1-NKG2D biAb was 200 $\mu\text{g}/\text{kg}$. Data from experiments using human PBMCs of two healthy donors. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$ using log-rank test.

anti-NKG2D component of the CS1-NKG2D biAb had a binding affinity in the nanomolar range, thus potentially leading to a more potent activation of NKG2D⁺ cytolytic effector cells (21). The possibility exists that CS1-NKG2D-activated effector cells could have bystander killing effects on the CS1⁻ MM cells. However, in our experiment using MM patient samples as target cells, we found a reduction of the CS1⁺CD38^{bright/+}CD138⁺ subset, but not of the CS1⁻CD38^{dim/+} subset. More experiments are needed to confirm the possible bystander effects from the CS1-NKG2D-activated effector cells.

The ligands for NKG2D are often expressed by tumor cells, both as membrane bound and in secreted forms, with the latter proposed as a mechanism of tumor escape (33). Zhang and colleagues proposed a biAb protein fusing an anti-CD3 scFv and the extracellular domain of NKG2D (30). This scFv-NKG2D fusion protein made use of the ligand binding ability of NKG2D to probe for NKG2D ligand-expressing tumor cells. However, there would be concern that this strategy, or others using similar NKG2D ligands as a binding domain (34), may be limited in efficacy because of the massive amounts of NKG2D ligands that can be shed from the tumor cell surface into both the microenvironment and the circulation, thereby chronically desensitizing NKG2D⁺ effector cells (35, 36). Thus, triggering NKG2D via the CS1-NKG2D biAb described herein may circumvent this potential limitation of effector cell desensitization. Previous reports suggest the NKG2D ligand MICA can shed from MM cell surfaces, which can desensitize NK cells (29). A low concentration of circulating soluble CS1 (no more than 10 ng/mL) is also detectable in serum of MM patients (28). These soluble targets may potentiate the effect of CS1-NKG2D biAb. However, our experiments show no significant difference in the E:T synapse formation and effectors' cytotoxicity against MM1.S cells in the presence of biAb with or without a soluble NKG2D-Fc chimera or a CS1 protein.

We demonstrated that both CD3⁺ T cells and CD56⁺ NK cells contributed to the *in vitro* cytotoxicity against CS1^{high} MM cells. This corroborated our hypothesis that the activation of different NKG2D⁺ immune effector cells provided improved cytotoxicity when compared with either effector population alone. We also observed that IL2 is required for the functional activation of

NKG2D induced by the CS1-NKG2D biAb. Our group and others have previously proposed using IL2 combined with targeted therapy for the treatment of non-Hodgkin lymphoma (37, 38). IL2 combined with zoledronate was demonstrated to be a feasible maintenance therapy for multiple myeloma in a phase II clinical trial (39). We foresee that the combination of IL2 and the CS1-NKG2D biAb deserves a future clinical exploration.

In our preclinical model of MM using NSG mice, those engrafted with CS1^{high} MM.1S MM cells showed significantly prolonged survival, whereas those engrafted with CS1^{int} MM NCI-H929 cells showed a less significant effect. This finding corroborates with the *in vitro* results, where the EC₅₀ for MM.1S MM cells was one log lower than that for NCI-H929 MM cells. These data suggest that the efficacy of our CS1-NKG2D biAb *in vivo* is likely to be dependent not only on the fraction of cytolytic immune effector cells, but also on surface density expression of CS1 by MM. However, approximately 95% of MM patients have high CS1 expression, and the expression remains stable after common MM drug treatment such as VDT-PACE or bortezomib (40). Thus, although the preclinical data appear promising in providing improved activity over the naked anti-CS1 mAb in MM, clinical efficacy might prove to be restricted to the CS1^{high} subset of MM patients and might be enhanced by improved immune modulation of NKG2D⁺ effector populations *in vivo*.

Disclosure of Potential Conflicts of Interest

W.K. Chan, M.A. Caligiuri, and J. Yu have submitted a patent through The Ohio State University for the CS1-NKG2D bispecific antibody described in this report. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: W.K. Chan, M.A. Caligiuri, J. Yu
Development of methodology: W.K. Chan, E.R. Barrett, A.M. Carter, A. Prasad
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): W.K. Chan, S. Kang, Y. Youssef, E.N. Glankler, E.R. Barrett, A.M. Carter, E.H. Ahmed, A. Prasad, L. Chen, D.M. Benson Jr
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): W.K. Chan, S. Kang, Y. Youssef, J. Zhang, J. Yu
Writing, review, and/or revision of the manuscript: W.K. Chan, S. Kang, Y. Youssef, E.R. Barrett, A. Prasad, L. Chen, D.M. Benson Jr, M.A. Caligiuri, J. Yu

Chan et al.

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Kang, E.R. Barrett, M.A. Caligiuri, J. Yu
Study supervision: W.K. Chan, S. Kang, M.A. Caligiuri, J. Yu

Acknowledgments

This work was supported by NIH grants CA89341, AI129582, CA095426, CA163205, CA016058, CA185301, NS106170, and CA068458 (to M.A. Caligiuri and/or J. Yu); 5T32CA009338 (to W.K. Chan); the Leukemia and Lymphoma Society Translational Research Award, the American Cancer Society Scholar Award (RSG-14-243-01-LIB), and a grant from the

Gabrielle's Angel Cancer Research Foundation (all to J. Yu). W.K. Chan was an NCI T32 fellow.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received November 13, 2017; revised February 28, 2018; accepted May 11, 2018; published first May 16, 2018.

References

- 2018 Cancer Stat Facts: Myeloma. <<https://seer.cancer.gov/statfacts/html/mulmy.html>>.
- Palumbo A, Anderson K. Multiple myeloma. *N Engl J Med* 2011;364:1046–60.
- Raje N, Longo DL. Monoclonal antibodies in multiple myeloma come of age. *N Engl J Med* 2015;373:1264–6.
- Touzeau C, Moreau P, Dumontet C. Monoclonal antibody therapy in multiple myeloma. *Leukemia* 2017;31:1039–47.
- van de Donk NW, Kamps S, Mutis T, Lokhorst HM. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma. *Leukemia* 2012;26:199–213.
- Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. *N Engl J Med* 2015;373:621–31.
- Chang X, Zhu Y, Shi C, Stewart AK. Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma. *Acta Biochim Biophys Sin (Shanghai)* 2014;46:240–53.
- Lacy MQ, McCurdy AR. Pomalidomide. *Blood* 2013;122:2305–9.
- López-Larrea C, Suárez-Alvarez B, López-Soto A, López-Vázquez A, Gonzalez S. The NKG2D receptor: sensing stressed cells. *Trends Mol Med* 2008;14:179–89.
- Spear P, Wu MR, Sentman ML, Sentman CL. NKG2D ligands as therapeutic targets. *Cancer Immunol* 2013;13:8.
- Verneris MR, Karimi M, Karami M, Baker J, Jayaswal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. *Blood* 2004;103:3065–72.
- Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, et al. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. *Blood* 2011;118:3301–10.
- Kuylensstierna C, Björkström NK, Andersson SK, Sahlström P, Bosnjak L, Paquin-Proulx D, et al. NKG2D performs two functions in invariant NKT cells: direct TCR-independent activation of NK-like cytotoxicity and co-stimulation of activation by CD1d. *Eur J Immunol* 2011;41:1913–23.
- Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. *Blood* 2005;105:251–8.
- El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, et al. The requirement for DNAM-1, NKG2D, and Nkp46 in the natural killer cell-mediated killing of myeloma cells. *Cancer Res* 2007;67:8444–9.
- Friberg G, Reese D. Blinatumomab (Blinxtyo); lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL). *Ann Oncol* 2017;28:2009–12.
- Veillette A, Guo H. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. *Crit Rev Oncol Hematol* 2013;88:168–77.
- Rajkumar SV, Kyle RA. Progress in Myeloma - A Monoclonal Breakthrough. *N Engl J Med* 2016;375:1390–2.
- Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. *Leukemia* 2014;28:917–27.
- Chu J, He S, Deng Y, Zhang J, Peng Y, Hughes T, et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. *Clin Cancer Res* 2014;20:3989–4000.
- Kwong KY, Baskar S, Zhang H, Mackall CL, Rader C. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity. *J Mol Biol* 2008;384:1143–56.
- Caligiuri MA, Chan WK, Yu J, inventors; Ohio State Innovation Foundation, assignee. Bivalent antibody directed against nkg2d and tumor associated antigens International patent WO2016134371A2. 2016-8-25.
- Haryadi R, Ho S, Kok YJ, Pu HX, Zheng L, Pereira NA, et al. Optimization of heavy chain and light chain signal peptides for high level expression of therapeutic antibodies in CHO cells. *PLoS One* 2015;10:e0116878.
- Chan WK, Suwannasena D, Throm RE, Li Y, Eldridge PW, Houston J, et al. Chimeric antigen receptor-redirection CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. *Leukemia* 2015;29:387–95.
- Caligiuri MA. Human natural killer cells. *Blood* 2008;112:461–9.
- Vallera DA, Todhunter DA, Kuroki DW, Shu Y, Sicheneder A, Chen H. A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma. *Clin Cancer Res* 2005;11:3879–88.
- Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. *Nat Immunol* 2006;7:524–32.
- Tai Y-T, Rice AG, Leiba M, Li X-F, Burger P, Song W, et al. Low levels of circulating CS1, a newly identified multiple myeloma (MM) antigen for a novel humanized HuLuc63 monoclonal antibody, is detected in MM patient sera and correlates with active disease. *Blood* 2007;110:1509–.
- Rebmann V, Schütt P, Brandhorst D, Opalka B, Moritz T, Nowrousian MR, et al. Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. *Clin Immunol* 2007;123:114–20.
- Zhang T, Sentman CL. Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells. *Cancer Res* 2011;71:2066–76.
- von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S, et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. *Blood* 2006;107:1955–62.
- Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. *Science* 1999;285:730–2.
- Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. *Nature* 2002;419:734–8.
- Stamova S, Cartellieri M, Feldmann A, Bippes CC, Bartsch H, Wehner R, et al. Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells. *Leukemia* 2011;25:1053–6.

35. Chitadze G, Bhat J, Lettau M, Janssen O, Kabelitz D. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. *Scand J Immunol* 2013;78:120–9.
36. Coudert JD, Scarpellino L, Gros F, Vivier E, Held W. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. *Blood* 2008;111:3571–8.
37. Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, et al. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. *Br J Haematol* 2002;117:828–34.
38. Khan KD, Emmanouilides C, Benson DM, Hurst D, Garcia P, Michelson G, et al. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma. *Clin Cancer Res* 2006;12:7046–53.
39. Buda G, Fazzi R, Carulli G, Galimberti S, Sammuri P, Orciuolo E, et al. Phase II study of the combination of interleukin-2 with zoledronic acid as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma. *Blood* 2016;128:5697–.
40. Szmania S, Balasa B, Malaviarachchi P, Zhan F, Huang Y, Draksharapu A, et al. CS1 is expressed on myeloma cells from early stage, late stage, and drug-treated multiple myeloma patients, and is selectively targeted by the HuLuc63 antibody. *Blood* 2006;108:660–.

Cancer Immunology Research

A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma

Wing Keung Chan, Siwen Kang, Youssef Youssef, et al.

Cancer Immunol Res 2018;6:776-787. Published OnlineFirst May 16, 2018.

Updated version Access the most recent version of this article at:
doi:[10.1158/2326-6066.CIR-17-0649](https://doi.org/10.1158/2326-6066.CIR-17-0649)

Supplementary Material Access the most recent supplemental material at:
<http://cancerimmunolres.aacrjournals.org/content/suppl/2018/05/16/2326-6066.CIR-17-0649.DC1>

Cited articles This article cites 38 articles, 14 of which you can access for free at:
<http://cancerimmunolres.aacrjournals.org/content/6/7/776.full#ref-list-1>

Citing articles This article has been cited by 1 HighWire-hosted articles. Access the articles at:
<http://cancerimmunolres.aacrjournals.org/content/6/7/776.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerimmunolres.aacrjournals.org/content/6/7/776>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.